Fragestellung: Bei 90 Patientinnen mit nodal-negativem Mammakarzinom wurde die prognostische Bedeutung von S-Phasefraktion (SPF) und MIB1-Proliferationsrate (MIB1-PR) nach einer mittleren Nachbeobachtungszeit von 34 Monaten (9–72) verglichen. Methode: An parallel geschnittenen, formalinfixierten Paraffinschnitten wurde SPF durchfluβzytometrisch und MIB1 (Ki-67) immunhistochemisch bestimmt. Ergebnisse: SPF korrelierte signifikant mit Tumorgröβe und Steroidhormonrezeptorstatus, MIB1-PR mit Tumorgrading. In der Univarianzanalyse waren SPF und MIB1-PR signifikante Prognosefaktoren für das rezidivfreie Überleben. In der Multivarianzanalyse war SPF jedoch der einzig statistisch signifikante Prognosefaktor, MIB1-PR und etablierte Prognosefaktoren blieben hier ohne signifikante Bedeutung. Schluβfolgerung: Die durchfluβzytometrisch bestimmte S-Phasefraktion war in dieser Studie prognostisch bedeutender als die immunhistochemisch ermittelte MIB1-Proliferationsrate und scheint für die klinische Anwendung beim nodal-negativen Mammakarzinom besser geeignet.

Keywords:
total S-phase fraction, MIB1 (Ki-67), node-negative breast cancer, breast cancer-prognosis
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.